Quanterix Announces the Simoa Accelerator
Quanterix announced the opening of The Simoa Accelerator.
Quanterix Corporation, a provider of high definition diagnostics, delivering ultrasensitive single molecule measurement, announced the opening of The Simoa Accelerator, a dedicated laboratory environment for custom assay development and clinical sample testing. Designed to provide access to the revolutionary Single Molecule Array (Simoa) HD-1 Analyzer, this state-of-the-art facility allows life science researchers to explore biomarkers and pathways with greater sensitivity and precision, paving the way for the development of new diagnostic tests and improved treatment of diseases in oncology, neurology, cardiology and other fields of medicine.
Read the full release here.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
